Skip to main content
SpringerLink
Log in
Book cover

On Bypass pp 125–140Cite as

The Inflammatory Response to Cardiopulmonary Bypass

  • Chapter

  • 2723 Accesses

Part of the book series: Current Cardiac Surgery ((CCS))

Abstract

Inflammation is a protective response of vascular tissue. Under normal circumstances, it functions as part of a surveillance system designed to quarantine and destroy harmful agents. The system is complex, with redundant cascades and amplification built into it. Because of this, inflammation is often exaggerated out of proportion to the inciting stimulus, and results in pathologic injury to the host. Certain types of clinical injury, such as severe trauma, burns, pancreatitis, and major surgery, can provoke such a profound response that it results in respiratory failure, coagulopathy, and multiorgan system dysfunction. These phenomena are often summarized under the term “systemic inflammatory response syndrome (SIRS).”

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   139.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Asimakopoulos G, Taylor KM. Effects of cardiopulmonary bypass on leukocyte and endothelial adhesion molecules. Ann Thorac Surg 1998;66:2135–2144.

    Article  CAS  PubMed  Google Scholar 

  2. Nishimura M, Ishikawa Y, Satke M. Activation of polymorphonuclear neutrophils by immune complex: possible involvement in development of transfusion-related acute lung injury. Transfus Med 2004;14:359–367.

    Article  CAS  PubMed  Google Scholar 

  3. Park JL, Lucchesi BR. Mechanisms of myocardial reperfusion injury. Ann Thorac Surg 1999;68:1905–1912.

    Article  CAS  PubMed  Google Scholar 

  4. Chenoweth DE, Cooper SW, Hugli TE, et al. Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins. NEJM 1981;304:497–503.

    CAS  PubMed  Google Scholar 

  5. Ernofsson M, Thelin S, Siegbahn A. Monocyte tissue factor expression, cell activation, and thrombin formation during cardiopulmonary bypass: a clinical study. J Thorac Cardiovasc Surg 1997:113:576–584.

    Article  CAS  PubMed  Google Scholar 

  6. Fujita T, Endo Y, Nonaka M. Primitive complement system—recognition and activation. Mol Immun 2004;41:103–111.

    Article  CAS  Google Scholar 

  7. Tonnesen E, Christensen VB, Toft P. The role of cytokines in cardiac surgery. Int J Cardiol 1996;53(supplement):Sl.

    Article  Google Scholar 

  8. Campbell DJ. The kallikrein-kinin system in humans. Clin Exp Pharm Physiol 2001;28:1060.

    Article  CAS  Google Scholar 

  9. Levy JH, Tanaka KA. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 2003;75:S715–S720.

    Article  PubMed  Google Scholar 

  10. Weerasinghe A, Taylor KM. The platelet in cardiopulmonary bypass. Ann Thorac Surg 1998;66:2145–2152.

    Article  CAS  PubMed  Google Scholar 

  11. Anaya-Prado R, Toledo-Pereyra LH, Lentsch AB, Ward PA. Research Review: Ischemia/reperfusion injury. J Surg Res 2002;105:248–258.

    Article  PubMed  Google Scholar 

  12. Riddington DW, Venkatesh B, Boivin CM, et al. Intestinal permeability, gastric intramucosal pH, and systemic endotoxemia in patients undergoing cardiopulmonary bypass. JAMA 1996;275:1007–1012.

    Article  CAS  PubMed  Google Scholar 

  13. Ohri SK, Desai JB, Gaer JAR, et al. Intraabdominal complications following cardiopulmonary bypass. Ann Thorac Surg 1991;52:826–831.

    Article  CAS  PubMed  Google Scholar 

  14. Asimakopoulos G. Systemic inflammation and cardiac surgery: an update. Perfusion 2001;16:353–360.

    CAS  PubMed  Google Scholar 

  15. Gu YJ, Mariana MA, Boonstra PW, et al. Complement activation in coronary artery bypass grafting patients without cardiopulmonary bypass: the role of tissue injury by surgical incision. Chest 1999;116:892–898.

    Article  CAS  PubMed  Google Scholar 

  16. Tarnok A, Hambsch J, Emmrich F, et al. Complement activation, cytokines, and adhesion molecules in children undergoing surgery with and without cardiopulmonary bypass. Ped Cardiol 1999;20:113–125.

    Article  CAS  Google Scholar 

  17. Tyrrell DJ, Horne AP, Holme KR, et al. Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv Pharmacol 1999;46:151–206.

    Article  CAS  PubMed  Google Scholar 

  18. Nelson RM, Cecconi O, Roberts GW, et al. Heparin oligosaccharides bind Land P-selectin and inhibit acute inflammation. Blood 1993;82:3253–3258.

    CAS  PubMed  Google Scholar 

  19. Fosse E, Moen O, Johnsson E, et al. Reduced complement and granulocyte activation with heparin coated cardiopulmonary bypass. Ann Thorac Surg 1994;58: 472–477.

    CAS  PubMed  Google Scholar 

  20. Steinberg BM, Grossi EA, Schmartz DS, et al. Heparin bonding of bypass circuits reduces cytokine release during cardiopulmonary bypass. Ann Thorac Surg 1995; 60:525–529.

    Article  CAS  PubMed  Google Scholar 

  21. Asimakopoulos G. The inflammatory response to CPB: the role of leukocyte filtration. Perfusion 2002; 17:7–10.

    Article  PubMed  Google Scholar 

  22. Chaney MA. Corticosteroids and cardiopulmonary bypass: a review of clinical investigations. Chest 2002; 121:921–931.

    Article  CAS  PubMed  Google Scholar 

  23. Kilger E, Weis F, Briegel J, et al. Stress doses of hydrocortisone reduce severe systemic inflammatory response syndrome and improve early outcome in a risk group of patients after cardiac surgery. Crit Care Med 2003;31:1068–1074.

    Article  CAS  PubMed  Google Scholar 

  24. Englberger L, Kipfer B, Berdat PA, et al. Aprotinin in coronary operation with cardiopulmonary bypass: Does “low dose” aprotinin inhibit the inflammatory response? Ann Thorac Surg 2002;73:1897–1904.

    Article  PubMed  Google Scholar 

  25. Tassani P, Augustin N, Barankay A, et al. High dose aprotinin modulates the balance between proinflammatory and anti-inflammatory responses during coronary artery bypass graft surgery. J Cardiothor Vasc Anes 2000; 14:682–686.

    Article  CAS  Google Scholar 

  26. Asimakopoulos G, Thompson R, Nourshargh S, et al. An anti-inflammatory property of aprotinin detected at the level of leukocyte extravasation. J Thorac Cardiovasc Surg 2000;120:361–369.

    Article  CAS  PubMed  Google Scholar 

  27. Hill GE, Pohorecki R, Alonso A, et al. Aprotinin reduces interleukin-8 production and lung neuttrophil accumulation after cardiopulmonary bypass. Aneth Anaig 1996;83:696–700.

    CAS  Google Scholar 

  28. Caliezi C, Wuillemin WA, Zeerleder S, et al. Cl-esterase inhibitor: An anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev 2000;52:91–112.

    CAS  PubMed  Google Scholar 

  29. Zwaan C, Kleine AH, Diris JHC, et al. Continuous 48-h Cl-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction. Eur Heart J 2002;23:1670–1677.

    PubMed  Google Scholar 

  30. Hack CE, Ogilvie AC, Eisele B, et al. Cl-inhibitor substitution therapy is septic shock and in vascular leak syndrome induced by high doses of IL-2. Intensive Care Med 1993;86:S19–S28.

    Article  Google Scholar 

  31. Horstick G, Berg, O, Heimann, A, et al. Application of Cl-esterase inhibitor during reperfusion of ischemic myocardium: Dose related beneficial versus detrimental effects. Circulation 2001;104:3125–3131.

    Article  CAS  PubMed  Google Scholar 

  32. Verrier ED, Shernan, SK, Taylor KM, et al. Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: A randomized trial. JAMA 2004;291:164.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Anesthesiology, Emory University Hospital, Atlanta, GA

    Roman M. Sniecinski MD & Jerrold H. Levy MD

Authors
  1. Roman M. Sniecinski MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jerrold H. Levy MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Cardiothoracic Surgery Clinical Perfusion, New York Presbyterian/Columbia College of Physicians and Surgeons, New York, NY

    Linda B. Mongero BS, CCP  & James R. Beck BS, CCP  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Humana Press Inc., a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Sniecinski, R.M., Levy, J.H. (2008). The Inflammatory Response to Cardiopulmonary Bypass. In: Mongero, L.B., Beck, J.R. (eds) On Bypass. Current Cardiac Surgery. Humana Press. https://doi.org/10.1007/978-1-59745-305-9_6

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-305-9_6

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-636-8

  • Online ISBN: 978-1-59745-305-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation